Rottapharm: Clinical Trials

4 trials sponsored by Rottapharm, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 completed, 1 withdrawn. 4 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Terminated 2, Completed 1, Withdrawn 1
Phase 31Withdrawn 1

Follow Rottapharm: new trials by email

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C
Legalon® SIL (Silibinin), Pegylated interferon alfa2b, Ribavirin - Hepatitis C, Chronic
Phase 2 / Phase 3WithdrawnRottapharm2013-08-012015-03-05
Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
Sillymarin, Placebo - Non-alcoholic Fatty Liver Disease
Phase 2CompletedUniversity of Malaya992012-06-012016-01-08
Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients
Silibinin (Legalon-SIL), Saline - Hepatitis C Virus Recurrence
Phase 2TerminatedRottapharm202011-08-012015-03-05
Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients
Silibinin, Placebo - HCV Recurrence After Liver Transplantation
Phase 2TerminatedRottapharm142010-09-012012-02-17

Conditions studied

Hepatitis C (1)  ·  Hepatitis C, Chronic (1)  ·  Non-alcoholic Fatty Liver Disease (1)

Interventions

Silybin (3)  ·  Ribavirin (1)  ·  Silymarin (1)  ·  Sodium Chloride (1)  ·  peginterferon alfa-2b (1)

Countries

Egypt (1)  ·  Italy (1)  ·  Malaysia (1)

Top investigators

Alfredo Di Leo, MD (1)  ·  Gamal Esmat, MD (1)  ·  Samer El-Kamary, MD (1)  ·  Sanjiv Mahadeva, MD, MRCP (1)  ·  Xavier Forns, Dr (1)

Results publications

PMID 24673819, PMID 28419855